Wednesday, August 4, 2021

Full-dose blood thinners reduce the need for organ support in moderately ill COVID-19 patients, but not in critically ill patients

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).

 

08/04/2021 05:15 PM EDT

The final analysis of trial data included 1,098 critically ill and 2,219 moderately ill hospitalized patients who received either a low or full dose of heparin for up to 14 days after enrollment.

This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Institutes of Health (NIH) · 9000 Rockville Pike · Bethesda MD 20892 · 301-496-4000 / TTY 301-402-9612 GovDelivery logo

No comments:

Post a Comment

The Best of Retail: Fashion Adapts to a Tough Reality

BoF is away for its annual break until 2nd January. In the meantime, we invite you to explore highlights of our news and analysis from t...